Health CarePharmaceuticals and Biotechnology
  • Price (USD)188.87
  • Today's Change-4.48 / -2.32%
  • Shares traded1.19m
  • 1 Year change-60.77%
  • Beta1.0666
Data delayed at least 15 minutes, as of Jun 28 2022 20:39 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Core Illumina products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. GRAIL is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed for genetic analysis. Customers use its platforms to perform whole genome, de novo, exome and ribonucleic acid (RNA) sequencing, and targeted resequencing of specific gene regions and genes. The Company's BeadArray technology produces arrays that can perform many assays simultaneously. Customers use its array-based genotyping consumables for a range of analyses, including diverse species, disease-related mutations, and genetic characteristics associated with cancer.

  • Revenue in USD (TTM)4.66bn
  • Net income in USD700.00m
  • Incorporated2000
  • Employees9.80k
  • Location
    Illumina Inc5200 Illumina WaySAN DIEGO 92122-4616United StatesUSA
  • Phone+1 (858) 202-4500
  • Fax+1 (858) 202-4766
  • Websitehttps://www.illumina.com
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ILMN:NSQ since
IDbyDNA IncDeal completed24 Jun 202224 Jun 2022Deal completed-2.42%--
Data delayed at least 15 minutes, as of Jun 28 2022 20:39 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Cognex Corporation1.08bn277.37m7.90bn2.26k29.375.8126.567.311.551.556.037.820.56233.057.52478,723.1014.4315.1715.9016.4072.0574.2725.6728.482.75--0.0044.8727.8814.3958.8614.223.8210.68
Bruker Corporation2.46bn282.00m9.53bn7.77k34.519.3725.513.881.851.8516.136.810.74651.706.65316,574.408.657.6812.0610.5050.3347.9411.599.571.7223.830.539512.9621.668.4675.6012.5319.920.00
Bio-Rad Laboratories, Inc.2.90bn-101.13m15.02bn7.90k--1.49469.695.19-4.88-4.8896.34340.100.20462.076.64366,558.30-0.714524.42-0.747726.3656.8055.45-3.4983.244.160.68240.10520.0014.817.1611.55177.08-3.10--
PerkinElmer, Inc.5.02bn740.94m18.29bn16.70k23.392.5415.923.646.206.2041.7556.970.42513.875.23300,534.306.286.637.127.7054.7052.3114.7614.321.439.160.40386.5533.9519.0929.5534.3225.800.00
Waters Corporation2.87bn704.55m19.89bn7.80k28.8653.1723.746.9411.4411.4446.566.210.91733.354.95367,679.6022.5416.2029.4819.4458.5758.4824.5724.161.7524.440.79390.0017.785.1532.845.8512.12--
Fortive Corp5.37bn650.40m19.97bn18.00k30.712.0918.723.721.811.8014.9726.680.35174.486.11298,444.404.375.235.246.4157.4755.0012.4315.080.73958.780.28114.0613.38-0.4635-58.09-4.77-14.6014.87
Avantor Inc7.55bn534.40m21.54bn13.50k37.365.8222.932.850.85620.856212.137.140.64065.945.93559,325.905.08--5.74--34.1732.517.932.421.184.810.6115--15.5260.60876.92--30.02--
Keysight Technologies Inc5.14bn1.02bn25.55bn14.50k25.686.7620.344.975.535.5327.7921.010.66552.346.95359,510.5013.247.6815.989.2563.9658.1719.9011.732.2616.640.32170.0017.0611.1142.5821.6913.84--
Mettler-Toledo International Inc.3.81bn793.32m25.95bn15.60k33.60306.8728.676.8134.0634.06163.623.731.194.156.39244,316.1024.8521.4335.6130.0758.2358.0020.8118.720.79422.860.95680.0020.518.1927.5814.88-2.79--
AMETEK, Inc.5.79bn1.04bn26.03bn18.50k25.173.7519.294.504.484.4824.8530.020.51345.166.78312,935.009.258.8410.5310.2034.4836.2018.0216.730.884116.900.267916.8822.177.6313.4814.0911.8317.32
Illumina, Inc.4.66bn700.00m30.38bn9.80k42.172.7930.566.524.584.5830.2369.390.38753.508.12475,102.005.8310.936.5812.9668.8168.8115.0323.161.54--0.13770.0039.7313.5416.1610.49-5.15--
Agilent Technologies Inc6.53bn1.26bn36.02bn17.40k29.087.0422.585.524.154.1521.4517.130.6263.485.65383,941.2012.1110.0514.6211.9953.9853.9519.3517.371.4919.010.361922.5218.368.5068.2921.246.3411.36
Roper Technologies Inc5.93bn1.00bn42.23bn19.30k42.593.1225.887.129.3627.0255.57127.950.23959.386.16307,165.804.045.664.596.4167.6765.4816.8720.411.227.190.354919.2019.038.8019.038.339.3113.40
Data as of Jun 28 2022. Currency figures normalised to Illumina Inc's reporting currency: US Dollar USD

Institutional shareholders

44.77%Per cent of shares held by top holders
HolderShares% Held
Baillie Gifford & Co.as of 31 Mar 202220.91m13.31%
The Vanguard Group, Inc.as of 31 Mar 202211.81m7.52%
Edgewood Management LLCas of 31 Mar 20228.74m5.56%
BlackRock Fund Advisorsas of 31 Mar 20227.55m4.81%
SSgA Funds Management, Inc.as of 31 Mar 20226.40m4.07%
Wellington Management Co. LLPas of 31 Mar 20223.74m2.38%
Loomis, Sayles & Co. LPas of 31 Mar 20223.54m2.25%
Polen Capital Management LLCas of 31 Mar 20222.63m1.68%
Geode Capital Management LLCas of 31 Mar 20222.63m1.67%
Walter Scott & Partners Ltd.as of 31 Mar 20222.39m1.52%
More ▼
Data from 31 Mar 2022 - 31 Mar 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.